Chimera Bioengineering
Biotechnology company developing next-generation engineered T‑cell therapies for solid tumors. The organization applies programmable, RNA-based gene regulation circuits to create conditionally armed CAR-T cells that deliver tumor-microenvironment‑modifying payloads locally, with the goal of improving potency while reducing systemic toxicity. The company is advancing preclinical candidates toward IND‑enabling studies and operates from South San Francisco.
Industries
Nr. of Employees
small (1-50)
Chimera Bioengineering
Patents
Products
CBIO-007 (lead conditionally armed CAR-T candidate)
Preclinical conditionally armed CAR-T cell therapy candidate designed to deliver tumor-microenvironment‑modifying payloads locally; demonstrated tumor elimination in multiple solid tumor xenograft models.
GOLD PLATFORM™
A proprietary native T-cell inspired genetic engineering platform that precisely controls gene expression in any cell therapy.
GOLD CONTROL™
Control system for engineered payloads to solve toxicity issues by managing where, when, and how much payload is produced.
Chimera Bioengineering CAR-T Platform
An engineered cell therapy platform designed to control protein expression and payload production using natural control codes, improving the efficacy and safety of CAR-T treatments for solid tumors.
MERCURY™
A platform technology that tunes expression of the CAR to solve the problem of too much or too little CAR expression.
CBIO-007 (lead conditionally armed CAR-T candidate)
Preclinical conditionally armed CAR-T cell therapy candidate designed to deliver tumor-microenvironment‑modifying payloads locally; demonstrated tumor elimination in multiple solid tumor xenograft models.
GOLD PLATFORM™
A proprietary native T-cell inspired genetic engineering platform that precisely controls gene expression in any cell therapy.
GOLD CONTROL™
Control system for engineered payloads to solve toxicity issues by managing where, when, and how much payload is produced.
Chimera Bioengineering CAR-T Platform
An engineered cell therapy platform designed to control protein expression and payload production using natural control codes, improving the efficacy and safety of CAR-T treatments for solid tumors.
MERCURY™
A platform technology that tunes expression of the CAR to solve the problem of too much or too little CAR expression.
Services
Internal platform for engineering conditional control circuits in cell therapies to localize payload expression and improve safety/efficacy (used to generate company pipeline).
Internal platform for engineering conditional control circuits in cell therapies to localize payload expression and improve safety/efficacy (used to generate company pipeline).
Expertise Areas
- CAR-T engineering
- Preclinical development and in vivo models
- Tumor microenvironment modulation
- RNA-based gene regulation for immune cells
Key Technologies
- CAR-T cell engineering
- Programmable RNA-based gene regulation circuits
- Conditional (location-specific) payload delivery
- Chimeric receptor engagement–dependent payload release
News & Updates
Press release announcing CEO appointment, AFCR BRACE Award win, preclinical proof-of-concept for lead candidate and progression toward IND-enabling studies.
Blog post describing company mission and values focused on creating safer, less toxic cell therapies that preserve patients' dignity.
Selected as winner of AFCR's 2021 BRACE Award, receiving award recognition and contributing investor connections and funding support.
Press release announcing CEO appointment, AFCR BRACE Award win, preclinical proof-of-concept for lead candidate and progression toward IND-enabling studies.
Blog post describing company mission and values focused on creating safer, less toxic cell therapies that preserve patients' dignity.
Selected as winner of AFCR's 2021 BRACE Award, receiving award recognition and contributing investor connections and funding support.